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Stem cell-based therapies critically rely on selective cell migration toward pathological or injured areas. We previously
demonstrated that human olfactory ectomesenchymal stem cells (OE-MSCs), derived from an adult olfactory lamina
propria, migrate speciﬁcally toward an injured mouse hippocampus after transplantation in the cerebrospinal ﬂuid and
promote functional recoveries. However, the mechanisms controlling their recruitment and homing remain elusive. Using
an in vitro model of blood-brain barrier (BBB) and secretome analysis, we observed that OE-MSCs produce numerous
proteins allowing them to cross the endothelial wall. Then, pan-genomic DNA microarrays identiﬁed signaling molecules
that lesioned mouse hippocampus overexpressed. Among the most upregulated cytokines, both recombinant SPP1/
osteopontin and CCL2/MCP-1 stimulate OE-MSC migration whereas only CCL2 exerts a chemotactic eﬀect. Additionally,
OE-MSCs express SPP1 receptors but not the CCL2 cognate receptor, suggesting a CCR2-independent pathway through
other CCR receptors. These results conﬁrm that OE-MSCs can be attracted by chemotactic cytokines overexpressed in
inﬂamed areas and demonstrate that CCL2 is an important factor that could promote OE-MSC engraftment, suggesting
improvement for future clinical trials.
1. Introduction
In both acute injury and neurodegenerative disorders of the
adult central nervous system (CNS), intrinsic regenerative
capacities usually fail to compensate neuronal loss. Therefore,
exogenous cell therapy is developed as a novel treatment,
where transplanted cells may replace dead cells, act as neuro-
trophic or neuroprotective agents, or deliver biotherapeutic
molecules [1]. Transplanted cells derived either from
embryonic stemcells, inducedpluripotent stemcells, or neural
stem/progenitor cells have shown great promises in various
models of cerebral pathology [2–4]. However, problems often
arose, including ethical issues, cell availability, graft rejection,
and risk of tumor formation [5–7]. Thus, testing alternative
cell types remains of great interest, especially adult peripheral
stem cells [8].
Adult stem cells from the humannasal olfactorymucosa, a
peripheral and permanently self-renewing nervous tissue,
stand as promising candidates [9–11].We characterized them
asmultipotentmesenchymal stem cellswith neurogenic prop-
erties and named them olfactory ectomesenchymal stem cells
(OE-MSCs) [11]. Beyond their capacity to generate neural
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cells, other properties support their potential usefulness for
autologous stem cell-based therapies: easily accessible in
every individual [12], they proliferate at a high rate
in vitro, while they do not seem to form tumors after
transplantation [11, 13]. In rodents, OE-MSCs successfully
improved models of myocardial infarct [14], spinal cord
trauma [15–17], cochlear damage [18, 19], or Parkinson’s dis-
ease [20]. We demonstrated their therapeutic potential in a
mouse model of excitotoxically induced neuronal death that
mimics an ischemic/hypoxic injury in the hippocampus [13].
We showed that human OE-MSCs survive after intracerebral
transplantation and promote learning and memory recovery.
Interestingly, they migrate speciﬁcally toward the lesioned
hippocampus after transplantation into either the controlat-
eral unlesioned side or the cerebrospinal ﬂuid (CSF) [13].
Moreover, this directed migration and cognitive recovery can
take place four weeks after the lesion, a delay required for
expanding high numbers of OE-MSCs from an individual in
the prospect of an autologous graft [11].
Though it is very eﬃcient to graft a large number of cells
into the desired brain area, transplantations into the brain
tissue or the CSF represent risky interventions, especially in
aged or fragile individuals. Systemic transplantation, into
either veins or arteries, constitutes a less invasive approach
(for reviews: [21, 22]). An increasing number of studies,
including clinical trials, report intravenous or intra-arterial
transplantation of mesenchymal stem cells against CNS
lesions or disorders [23]. Thus, selective migration toward a
pathological or traumatized area is a critical step in stem cell
regenerative medicine. For eﬀective therapy, stem cell
homing is necessary to reduce migration to other areas while
allowing the delivery of stem cells via less invasive routes and,
possibly, excluding unwanted side eﬀects [24]. Many studies
demonstrated the tropism of both endogenous and
transplanted stem/progenitor cell types for inﬂamed tissues,
including hypoxic-ischemic areas, glial tumors, and other
injury-associated zones where neuroinﬂammatory responses
involve components of the innate immune system [25–29].
Inﬂammation strongly upregulates chemotactic cytokines in
cerebral pathologic areas, and these molecules have been
implicated in the migration of immune and stem cells to
these sites [24]. Identifying the molecular pathways directing
stem cell migration might be crucial for improving therapeu-
tic intervention in several neurological diseases [30]. We
recently demonstrated that OE-MSCs strongly express
matrix metalloproteinases (MMPs) such as MMP2, MMP9,
and MT1-MMP and showed their importance in OE-MSC
migration [31]. However, the molecular mechanisms regulat-
ing OE-MSC attraction and homing to injured brain areas
have not yet been investigated.
The present study focuses on how olfactory cells trans-
planted into the circulation manage to reach the lesioned
brain, crossing ﬁrst the blood-brain barrier (BBB) and then
migrating through the nervous parenchyma. To better
understand the cellular and molecular mechanisms at play,
we used an experimental approach based on in vitro models
of BBB, an exhaustive proteomic analysis of proteins secreted
by OE-MSCs, a pan-genomic microarray study of molecules
released by lesioned cells and cell migration assays.
2. Materials and Methods
2.1. Cell Culture. Following a protocol approved by the
local ethical committee (Comité de Protection des
Personnes, Marseille, France, ﬁle number 205 016), human
nasal olfactory mucosae were obtained by biopsy during
routine nasal surgery under general anesthesia. Biopsies
were immediately placed in growth medium containing
DMEM/Ham F12 supplemented with 10% fetal bovine
serum (FBS) and 100 units/mL of penicillin and 100μg/mL
of streptomycin (Invitrogen/Life Technologies). OE-MSCs
were puriﬁed from the lamina propria and cultured as
described before [11, 13]. All experiments were performed
using OE-MSCs obtained after 4 to 12 passages from the ini-
tial cultures. OE-MSCs from three diﬀerent donors were used
in this study. When needed, OE-MSCs were infected with a
GFP lentiviral vector. The acute monocytic leukemia cell
line THP1 used as positive control in RT-qPCR experiments
was obtained from the American Type Culture Collection
and cultured in RPMI 1640 containing 10% FBS and
100 units/mL of penicillin and 100μg/mL of streptomycin.
2.2. Blood-Brain Barrier (BBB) Model and Permeability Test.
To analyze OE-MSC transmigration, we used a model of BBB
with two compartments separated by a porous membrane
(pore size: 1μm), already described by Molino et al. [32].
Brieﬂy, rat endothelial cells from blood cerebral microvessels
were cultured in the top compartment on polyethylene insert
ﬁlters coated with collagen IV and ﬁbronectin, at a cell den-
sity of 500,000 per insert in 6-well culture plates. Rat glial
cells were cultured in the bottom compartment at a density
of 16,000 cells/cm2. For both compartments, the culture
medium was composed of DMEM/Ham F12 supplemented
with 20% bovine serum depleted in platelets, 2 ng/mL ﬁbro-
blast growth factor 2 (FGF2), and 500nM hydrocortisone
[32]. For each experiment, 3 to 4 conditions were evaluated
in duplicate: 0, 120,000, and 500,000 OE-MSCs were seeded
on top of the endothelial cells, then incubated for 24 h. Per-
meability to the Lucifer yellow dye (LY, Sigma-Aldrich
L0259) was next measured over 60min using ﬂuorimetry,
as described [32].
2.3. OE-MSC Secretome Analysis. We collected the condi-
tioned medium (CM) of OE-MSCs cultured for 3 days at
conﬂuency in T75 ﬂasks containing 10mL of serum-free
DMEM/Ham F12 with 1% insulin-transferrin-selenium-eth-
anolamine (ITS-X, Invitrogen/Life Technologies) and
penicillin/streptomycin. One culture ﬂask containing only
serum-free medium served as negative control. The CM
was ﬁltered through sterile 0.2μm ﬁlters; 1% protease inhib-
itor cocktail (Calbiochem 599131) was added, and the CM
was immediately frozen at −80°C. This procedure was
repeated for three more days, and the CMs were combined.
The CMs were concentrated and desalinated in Ultracel 3-
K Amicon ultracentrifugal ﬁlters with a ﬁrst centrifugation
at 3220g during 30min and, after adding 10mL of sterile
water (B. Braun), a second centrifugation at 3,220g for
20min. Of the obtained 500μL of concentrated CM, 50μL
were loaded onto a polyacrylamide gel (4–20% mini-
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Protean TGX gel, Bio-Rad 456-1096) and the proteins sepa-
rated by electrophoresis were stained with EZ Blue staining
reagent (Sigma-Aldrich G1041). After elution from the gel,
peptides were obtained by trypsin hydrolysis, separated by
HPLC (Ultimate 3000 Rapid Separation LC Systems, Dionex),
and sequenced by tandem mass spectrometry (Q-Exactive
Thermoﬁscher). Secreted proteins were identiﬁed using the
Swiss Prot data bank (http://web.expasy.org/docs/swiss-prot_
guideline.html) and analyzed using the Ingenuity Pathway
Analysis software (https://www.qiagenbioinformatics.com/
products/ingenuity-pathway-analysis/).
2.4. Hippocampal Excitotoxic Lesions in Mice. Animal
experiments were approved by the Ethics Committee of the
Medical Faculty of Marseille and were carried out in
accordance with the guidelines published in the European
Communities Council Directive of November 24, 1986 (86/
609/EEC). All eﬀorts were made to minimize animal suﬀer-
ing and to reduce the number of mice. Unilateral or bilateral
lesions of the hippocampus on ten-week-old male Balb/c
mice (Charles River, L’Arbresle, France) were performed
using ibotenic acid (Sigma-Aldrich, Saint-Quentin-Fallavier,
France), an NMDA agonist, leading to the loss of neuronal
cells in the sites of injection by cellular excitotoxicity, as
described in our previous study [13]. One day after the
lesion, hippocampal lesion eﬃciency was controlled using
magnetic resonance imaging (MRI), as previously
described [13].
2.5. Microarray Experiments. Four weeks after ibotenic acid-
induced injury, bilaterally lesioned mice (n = 3) and control
mice (n = 3) were decapitated. Brains were quickly removed,
and hippocampi were dissected under RNAse-free condi-
tions before being immediately placed in RNA later (Qiagen,
Courtaboeuf, France) and stored at −80°C. Total RNA was
isolated and treated with DNAse using the RNeasy Lipid
Tissue Mini Kit (Qiagen). RNA concentration and purity
were determined using a NanoDrop-1000 Spectrophotome-
ter (NanoDrop Technologies, Thermo Fisher Scientiﬁc, Ill-
kirch-Graﬀenstaden, France). RNA quality was assessed
with an Agilent 2100 Bioanalyser (Agilent Technologies,
Massy, France). For each sample, cDNA was generated from
600ng of total RNA with an Agilent Quick Amp Kit (Agilent
Technologies). Then complementary RNA was synthesized,
ampliﬁed, and labeled with cyanine 3 dye according to the
manufacturer’s protocols. Cyanine 3-labeled cRNA
(1.65μg) was fragmented and hybridized to the Agilent
Whole Mouse Genome Oligo Microarray 4x44k at 65°C for
17 hours. After washing, ﬂuorescence intensity at each spot
was assayed using a G2565BA Microarray Scanner (Agilent).
After extraction with Feature Extraction Software 9.5.3
(Agilent), data were normalized (background subtraction
and quantile normalization) using AgiND library developed
under R software for Agilent microarray data normalization
and visualization. A fold change ratio (each lesioned hippo-
campus against pooled control hippocampus) was calculated
for every spot. Data are available on the ArrayExpress
database (accession number E-MEXP-2682).
2.6. Real-Time Quantitative PCR. Four weeks after injury,
overexpression of cytokine candidates was assessed using
real-time quantitative PCR (RT-qPCR) in control (n = 5)
and lesioned (n = 6) mice. According to the manufacturer’s
protocol (Invitrogen/Life Technologies, Saint Aubin,
France), 1μg total RNA from hippocampi (prepared as
described above) was submitted to reverse transcription
using hexanucleotides and Moloney murine leukemia virus
(MMLV) reverse transcriptase. Quantitative PCR experi-
ments were carried out with the 7500 Fast Real-Time PCR
System (Applied Biosystems/Life Technologies). All reac-
tions were performed using TaqMan Fast Universal PCR
Master Mix and TaqMan® Gene Expression Assay probes
(Applied Biosystems, see Supplementary Table 2 available
online at https://doi.org/10.1155/2017/1478606 for assay
IDs). For each experiment, 25 ng of previously prepared hip-
pocampus cDNA were used. Samples were run in duplicates
and analyzed with the 7500 Software v2.0 (Applied Biosys-
tems). Relative expression levels were determined according
to the ΔΔCt method, the Gapdh gene serving as endogenous
control for normalization. Receptor expression in human
OE-MSCs was assessed with the same protocol (see
Supplementary Table 2 for assay IDs). In this case, data were
normalized using the human housekeeping gene ABELSON,
as previously described [33]. For each OE-MSC donor,
RNA extractions were performed from three independent
cultures and the reported values are the mean of these three
independent experiments, each performed in duplicate.
2.7. Tissue Processing. One month after surgery, unilaterally
injured mice (n = 3) were deeply anesthetized (sodium pen-
tobarbital, i.p.) and transcardially perfused (saline then 4%
paraformaldehyde). Brains were extracted, postﬁxed over-
night in cold paraformaldehyde, and transferred to a 30%
sucrose solution before being processed for cryostat section-
ing (Leica Microsystems, Wetzlar, Germany). Coronal sec-
tions (35μm thick) were serially collected and kept ﬂoating
at −20°C in cryoprotectant (30% glycerol, 30% ethylene
glycol in 0.05M phosphate-buﬀered saline (PBS)) until
processed for immunostaining.
2.8. Immunostaining. For tissue staining, after washing in
PBS, ﬂoating sections were incubated 1 hour at room tem-
perature (RT) with blocking buﬀer (3% bovine serum
albumin, 0.1% Triton X-100 in PBS) and overnight at
4°C with the following primary antibodies diluted in
blocking solution: mouse monoclonal anti-GFAP (1/300,
Millipore/Chemicon, Molsheim, France) or rabbit anti-
Iba1 (1/200, Wako Pure, Chemical Industries, Osaka,
Japan). Then, slices were rinsed (3× 5min) in PBS and
incubated for 90min at RT with cross-adsorbed Alexa-
Fluor 488- or 594-conjugated anti-rabbit or anti-mouse
secondary antibodies (1/500, Jackson Immunoresearch,
West Grove, PA, USA) in the dark. After several washes
in PBS, slices were counterstained with 0.5μg/mL Hoechst
blue (#33342, Sigma-Aldrich) for 30min at RT and
mounted with ProLong Gold Antifade reagent (Invitro-
gen/Life Technologies). Images were acquired with an
inverted Axio Observer microscope (Zeiss, Jena, Germany)
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equipped with DAPI, FITC, and rhodamine epiﬂuores-
cence ﬁlters, using the mosaic mode of the Axiovision
software (Zeiss).
For cytochemistry on the BBB model, OE-MSC transmi-
gration was carried out on the 12-well plate insert ﬁlters and
cells were ﬁxed for 15min in 4% paraformaldehyde. After
three washes, ﬁlters with the cells were gently dissociated
from the plastic inserts with a razor blade and incubated for
1 hour at RT with a blocking buﬀer and, overnight at 4°C,
with the mouse anti-Claudin-5 primary antibody (1/100,
Invitrogen), diluted in the blocking solution. Cells were incu-
bated with the appropriate ﬂuorescent secondary antibody
for 1 hour at RT (1/500, Alexa Fluor 594-conjugated anti-
mouse) while nuclei were labeled with Hoechst blue. Cells
were washed and mounted in Prolong Gold antifade reagent.
2.9. Chemotaxis Assay in Modiﬁed Boyden Chambers. OE-
MSCs, cultured in serum-containing medium, were detached
by trypsin/EDTA, counted, and seeded into the upper cham-
ber of cell culture inserts for 24-well plates with translucent
polyethylene terephthalate (PET) ﬁlter membranes with
8μm diameter pores (BD Falcon™, BD Biosciences, Le Pont
de Claix, France) at a density of 1.2× 104 cells per insert, in
a ﬁnal volume of 200μL of serum-free medium with 1%
ITS-X. Cells were allowed to migrate through the membrane
ﬁlter after cytokines were added to the lower chamber at var-
ious concentrations (human recombinant C3A and mouse
recombinant SPP1, R&D systems; human recombinants
CXCL10, CCL2, and SPP1, Peprotech; and mouse recombi-
nant SPP1, Invitrogen/Life Technologies) in a ﬁnal volume
of 400μL of the same serum-free medium. Control inserts
were prepared by substituting each cytokine with its reconsti-
tution buﬀer. After 12 h of incubation (37°C in 5% CO2),
inserts were delicately rinsed in PBS, OE-MSCs were ﬁxed
with 4% paraformaldehyde, and their nuclei were stained
with 1μg/mL Hoechst blue (#33242, Invitrogen/Life
Technologies). Membrane ﬁlters were observed using a
Nikon E800 (Nikon, Champigny-sur-Marne, France) upright
microscope equipped with epiﬂuorescence and DAPI ﬁlter
and an Orca-ER CCD camera (Hamamatsu Photonics,
Hamamatsu, Japan). For quantitative assessment, the num-
ber of stained cells on each side of the membrane was manu-
ally counted and the percentage of migrating cells was
calculated per ﬁeld. Forty random ﬁelds were analyzed per
membrane ﬁlter, using a 40x objective. Reported values are
the mean percentage of migrating cells per membrane of at
least three independent experiments performed in triplicate.
Random cell motility (chemokinesis) was assessed by adding
an equal concentration of cytokines in both upper and lower
wells of the chamber.
2.10. Agarose Spot Assay. In order to quantify cytokine eﬀect
on OE-MSC migration, we also performed agarose spot
assay, as previously described [34, 35] with few alterations.
Low-melting point agarose (Ultrapure™ low-melting aga-
rose, Invitrogen/Life Technologies) was diluted into sterile
PBS in order to make a 1% agarose solution. This solution
was heated until all agarose particles were dissolved and then
cooled down to 37°C. Preheated cytokine-containing
solution (37°C in serum-free medium with 1% ITS-X) was
then added to the melted 1% agarose to produce a ﬁnal con-
centration of 0.5% agarose and a 10μg/mL cytokine solution.
A negative control agarose solution was prepared by using
reconstitution buﬀer for each cytokine. For each condition,
10 independent drops of 5μL (maintained at 37°C) were
pipetted onto a sterile 30mm diameter glass coverslip previ-
ously placed into a 35mm cell culture Petri dish. The dish
was then cooled for 10min at 4°C to allow the agarose spot
to solidify. The petri dishes were then gently ﬁlled with
2mL of serum-free medium with 1% ITS-X and placed in
an incubator (37°C in 5% CO2) for 10min. Then, OE-MSCs
cultured in serum-containing medium were trypsinised and
resuspended in the serum-free medium. Every dish contain-
ing the agarose spots was seeded with 2× 105 cells and then
incubated for 24 h (37°C in 5% CO2). The number of cells
invading underneath the agarose spot was manually counted
using standard phase contrast light microscopy. Imaging was
performed using an inverted phase microscope (TE300,
Nikon) with a 10x objective, and images were acquired using
an Orca-ER CCD camera (Hamamatsu Photonics) and Axio-
vision software (Zeiss). The total number of invading cells
per agarose spot was counted, and the reported values are
the mean number of cells per spot of at least three indepen-
dent experiments.
2.11. Statistics. All data are presented as mean± SEM. Data
were analyzed using SPSS/PC + statistics 11.0 software (SPSS
Inc., Chicago, IL). Kruskal-Wallis, ANOVA, and Mann–
Whitney U tests were used appropriately to detect any signif-
icant diﬀerence, as indicated in each ﬁgure legend. The min-
imal threshold for signiﬁcance was set at p < 0 05.
3. Results
3.1. Human OE-MSCs Migrate through an In Vitro BBB
Model. To visualize the diapedesis phenomenon, we plated
GFP-positive OE-MSCs on an in vitro model of blood-
brain barrier. At low magniﬁcation and using phase contrast
(Figure 1(a)) and epiﬂuorescence (Figures 1(a) and 1(b)), we
observed apparently undiﬀerentiated stem cells adhering
onto the apical surface of the endothelial cell layer as well
as diﬀerentiating-looking cells, spreading out on the mem-
brane of the insert and underneath the basal side of the
BBB. To cross the barrier, the stem cells can either go through
one endothelial cell (transcellular) or between endothelial
cells (paracellular). For the latter, they possibly perforate
the layer, in various places, to make their way to the other
side, as observed in Figures 1(c) and 1(d). Using an anti-
Claudin 5 antibody to label tight junctions, we revealed
breaches in the BBB, close to two GFP+ stem cells. To ascer-
tain barrier crossing, we used the orthogonal projection bars
of a confocal microscope, as shown in Figure 1(e) (top and
right side bars): the migrating cell (green) is clearly located
under the Claudin-positive endothelial cell layer (red).
Figure 1(f) displays a GFP-positive globular OE-MSC during
migration (white arrowhead) and an attached OE-MSC
under the BBB (white arrow).
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Figure 1: Migration of human olfactory stem cells through the blood-brain barrier (BBB). (a–f) GFP-positive human OE-MSCs were seeded
at two densities (120,000 and 500,000 cells per well) on a BBB model, and their diapedesis was observed 24 hours later. Phase contrast (a) and
ﬂuorescent (b) photomicrographs displaying globular OE-MSCs adhering on the external surface of the endothelial cell layer and attached
OE-MSCs with processes indicating their localization on the membrane and under the BBB. Scale bar: 100 μm. (c) Anti-Claudin 5
antibody identiﬁes endothelial tight junctions (red). (d) Immunostaining reveals openings in the BBB (white dotted lines) and the
integration of two OE-MSCs under the BBB. Scale bar: 10 μm. (e, f) Focus on migrating cells. (e) The sequential plane bars (spaced
0.4 μm), on the top and the right, indicate that the migrating cell (green) is located under the Claudin 5-stained endothelial cells (red). (f)
Focus on a GFP-positive OE-MSC during transmigration (white arrowhead) and on another one installed under the BBB (white arrow).
(g) One day after seeding, BBB permeability was measured by a Lucifer yellow test. The ﬂuorometric measurement of Lucifer yellow
indicates that stem cell increases BBB permeability at both cell densities (n = 4). ∗p < 0 05.
5Stem Cells International
The observed perforation of the barrier led us to measure
its permeability. We cocultivated stem and endothelial cells
during 24 hours, and using a 1-hour long Lucifer yellow test,
we observed a signiﬁcant increase in barrier permeability, for
both cell densities: p = 0 042 at 120,000 cells per well and
p = 0 020 at 500,000 cells per well (Figure 1(g)).
3.2. OE-MSCs Secrete Proteins Involved in Homing and
Transmigration. In order to identify diapedesis mechanisms,
we sought soluble factors secreted by OE-MSCs. It was sur-
mised that some of them are responsible, at least partly, for
the transmigration ability of olfactory stem cells. To this
end, we analyzed the medium in which the stem cells were
cultured for 3 days, called conditioned media. After ﬁltration,
puriﬁcation of the protein fraction, and migration on agarose
gel, we identiﬁed the proteins present using a mass spectrom-
eter. A total of 629 human proteins were characterized (see
Supplementary Table 1). Nearly two out of ﬁve (38%=239/
629) of these proteins are associated with cell movement,
transmigration, and/or homing. The full list of 629 proteins
was analyzed with the Ingenuity software. As indicated in
Figure 2(a), the ﬁve top canonical pathways are associated
with diapedesis/extravasation (3/5), actin cytoskeleton (1/
5), and axon guidance (1/5). Ingenuity Pathway Analysis also
identiﬁed the 34 proteins associated with transmigration, and
we propose the diagram in Figure 2(b) to account for possible
OE-MSC diapedesis mechanisms.
3.3. Lesioned Hippocampi Are Inﬂamed One Month after
Injury. We then wanted to evaluate the role of inﬂammatory
processes in OE-MSC selective migration toward lesioned
hippocampi [13]. We ﬁrst usedMRI to validate the speciﬁcity
and eﬃcacy of the lesion in each animal. Twenty-four hours
after surgery, we visualized the injected/lesioned area and
conﬁrmed that only the targeted hippocampus was aﬀected
(Figure 3(a)). Along this line, brain tissue analysis at four
weeks postlesion showed a dramatic cell loss in the injected
hippocampal cell layers and more particularly in the CA1
and dentate gyrus regions (Figures 3(b) and 3(c)). Addition-
ally, we observed that neuroinﬂammation markers such as
Gfap and Iba1, which, respectively, mark reactive astrocytes
and microglia, were strongly and speciﬁcally expressed in
Five main pathways involving proteins secreted by OE-MSCs
Agranulocyte adhesion and diapedesis 29 190
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179
454
0 10 20 30 40 50 60 70 80 90 100
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31
32
24
43
Leukocye extravasation signaling
Actin cytoskeleton signaling
Granulocyte adhesion and diapedesis
Axonal guidance signaling
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ACTA2STC1
ICAM1 JAM3 VCAM1 ITGB1 ITGAV
CXCL2
CXCL3 CXCL10
IL6CXCL12
CXCL8
COL4A1
ALCAM
LDLR
RAC1
FN1
LGALS1
PDCD1LG2
AOC3APPPVRTHY1
CD44
ADAM10
Blood-brain barrier
Olfactory ectomesenchymal
stem cell
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Figure 2: Bioinformatic analysis of the OE-MSC secretome. The 629 proteins secreted by OE-MSCs identiﬁed by mass spectrometry were
analyzed using the Ingenuity Pathway software. (a) List of the ﬁve top canonical pathways, ranked by decreasing ratio values (percentage
of identiﬁed secreted proteins in the pathway over a total of known proteins involved in this pathway). The numbers in the darker boxes
indicate the number of OE-MSC-secreted proteins associated with the pathway; the number at the end of the bar represents the sum of
known proteins associated with each speciﬁc pathway. (b) Schematic view of the 34 OE-MSC-secreted proteins involved in
transmigration. The list of secreted proteins associated with cell movement and homing are found in Supplementary Table 1.
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the lesioned areas (Figures 3(d)–3(g)). Thus, one month after
injury, the lesioned hippocampi still displayed inﬂammation
hallmarks, making this model highly suitable for further gene
expression analyses.
3.4. Lesioned Hippocampi Overexpress Genes Involved in Cell
Chemoattraction. In order to ﬁnd candidate OE-MSC che-
moattractants within lesioned brain tissue, we established
the gene expression proﬁles of control and lesioned
(a)
Hoechst Hoechst
(b) (c)
Iba1/Hoechst Iba1/Hoechst
(d) (e)
Gfap/Hoechst Gfap/Hoechst
(f) (g)
Figure 3: Inﬂammation in the lesioned hippocampus. (a) MRI assessment of an in vivo lesion, 24 hours after injection of ibotenic acid in the
right hippocampus. Example of an axial contiguous T2-weighted image (slice thickness = 500μm, TEeﬀ= 60ms, TR = 3000ms, rare
factor = 8; 8 averages). The hypersignal (bright intensity) in the right hippocampus reveals the extent of the injury. Hoechst blue staining
on representative coronal brain sections at the dorsal hippocampal level shows the extent of ibotenic acid-induced neuronal death, one
month after the lesion (c), in CA1 and dentate gyrus, in comparison with the unlesioned (b) controlateral hippocampus (white arrows).
(d–g) Brain sections were immunostained with anti-Iba1 (in green) and anti-Gfap (in red) antibodies. The four-week-lesioned
hippocampus displays numerous activated astrocytes and microglia, in comparison with the healthy controlateral hippocampus. Similar
images were obtained with at least three brains. Scale bar: 0.5mm.
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hippocampi. Four weeks after the lesion, hippocampi were
isolated and processed for pan-genomic microarray analysis
(ArrayExpress database, accession number E-MEXP-2682).
The data indicated that 114 transcripts with a fold change
above 2.5 were upregulated in the lesioned hippocampi.
Interestingly, the DAVID Functional Annotation Clustering
Tool showed that overexpressed transcripts clustered into
functional groups, indicating in particular that 53% of these
genes are involved in immune and inﬂammatory processes.
More importantly, among the strongly upregulated tran-
scripts (fold change above 10), four were coding for mole-
cules already known for their chemotactic properties on
immune cells and other stem cell types (Table 1). Indeed,
transcripts for C3 and Spp1, two members of the cytokine
family, as well as those for the Ccl2 and Cxcl10 chemokines
appeared as highly interesting hits. Beside those four candi-
dates, other chemotactic cytokine transcripts (Ccl4, Ccl5,
Ccl7, Ccl12, Ccl19, Cxcl1, and Cxcl16) were also signiﬁcantly
overexpressed. On the contrary, other genes did not display
signiﬁcant changes though they code for cytokines or growth
factors with a chemoattractant role on diﬀerent types of stem
cells, such as Cxcl12/Sdf1, stem cell factor (SCF), Igf1, Hgf,
Pdgfa, and Vegfa. In the subsequent experiments, we decided
to focus on the four most overexpressed chemotactic cyto-
kines. To conﬁrm gene expression data from our microarray
analysis, we assessed the expression level of C3, Spp1, Ccl2,
and Cxcl10 by RT-qPCR (Figure 4). Here again, the selected
cytokines were signiﬁcantly overexpressed (p < 0 01 for each)
in lesioned hippocampi (n = 6) when compared to nonle-
sioned hippocampi (n = 5) (Figures 4(a)–4(d)). Noticeably,
gene expression analysis on another set of genes involved
in brain inﬂammation—that is, Gfap, F4/80, Tnfa, and
Il1b—conﬁrmed the inﬂammatory state of the injured
hippocampi, one month after lesion (Figures 4(e)–4(h)).
3.5. CCL2 and SPP1 Stimulate OE-MSC Migration In Vitro.
Our converging data led us to evaluate the eﬀects of the
human recombinant cytokines C3A, CCL2, SPP1, and
CXCL10 on human OE-MSCmigration. To this end, we used
modiﬁed Boyden chambers and agarose spot assays to assess
the chemotattractant potential of these molecules on OE-
MSCs. Interestingly, only CCL2 and SPP1 stimulated OE-
MSC migration in modiﬁed Boyden chambers. Indeed, we
observed a signiﬁcantly increased number of migrating cells
in response to either of these two cytokines as early as 12
hours after treatment (Figures 5(a)–5(d)). Noticeably, our
results showed a dose-dependent eﬀect, starting to be signif-
icant when the concentration reached 400ng/mL for both
CCL2 (p < 0 01) and SPP1 (p < 0 001) (Figure 5(d)), and no
cumulative eﬀect when both cytokines were used
(Figure 5(e)). The total number of cells was unchanged under
these conditions, thus excluding an artifactual eﬀect due to
OE-MSC increased proliferation. Of note, these results have
been consistently reproduced on OE-MSCs derived from
three additional individuals (data not shown). Similarly, we
observed that only CCL2 and SPP1 signiﬁcantly stimulate
the migration of OE-MSCs under jelliﬁed agarose drops con-
taining the cytokines at 10μg/mL (p < 0 001 for both), after
24 hours of migration (Figures 5(f)–5(i)). Here again, no
additive eﬀect was observed when the two cytokines were com-
bined (Figure 5(j)). Altogether, our results indicate that CCL2 is
more potent than SPP1 in the modiﬁed Boyden chamber assay
(242.7±18.6% for hCCL2 and 181.4±19.5% for hSPP1;
p < 0 05) as well as in the agarose spot assay (391.5±27.2%
for hCCL2 and 187.1±21.7% for hSPP1; p < 0 001), when
comparing the cytokines at the concentration with maximum
eﬃcacy. With these data in hand, we hypothesized that the
same cytokines might play a role in the migration of OE-MSC
into lesioned mouse hippocampi [13]. We used a similar
strategy with the mouse recombinant Ccl2 and Spp1 cytokines.
Similarly to human CCL2 in the modiﬁed Boyden chamber
assay, mouse Ccl2 stimulated OE-MSC migration, starting
from the concentration of 400ng/mL (p < 0 05) (Figure 6(a)).
Surprisingly, a higher concentration of mouse Spp1
(4,000 ng/mL) was required to observe an eﬀect (p < 0 01)
(Figure 6(a)). Finally, the agarose spot assay conﬁrmed that
Ccl2 and Spp1 were able to stimulate OE-MSC migration
(p < 0 001 for both) with Ccl2 being clearly more potent
than Spp1 (Figure 6(b)). Altogether, our results validated
that CCL2 and SPP1 are two candidate molecules that
could participate in the directed migration of OE-MSCs
toward a speciﬁc lesioned area.
3.6. CCL2 Exerts a Chemotactic Eﬀect on OE-MSCs In Vitro.
In order to further elucidate CCL2 and SPP1 mechanisms
of action on OE-MSC migration, we then evaluated the rela-
tive contribution of random cell motility (chemokinesis) and
gradient-dependent cell migration (chemotaxis) of human
OE-MSCs in response to CCL2 and SPP1. To distinguish
chemotaxis from chemokinesis in modiﬁed Boyden cham-
bers, we compared the eﬀect of the cytokines placed either
Table 1: Dysregulated transcripts with a fold change above 10 in the
lesioned hippocampus, in comparison with the unlesioned
hippocampus, one month after the lesion.
Gene
symbol
Gene/protein name
Fold
change
C3 Complement component 3 162.5
Lyz1 Lysozyme 1 31.4
Mmp3 Matrix metalloproteinase 3 27.1
Ccl2 Chemokine (C-C motif) ligand 2 24.2
Lyz2 Lysozyme 2 23.7
Clec7a C-type lectin domain family 7, member a 23.5
Tnfaip2
Tumor necrosis factor, alpha-induced
protein 2
14.1
Tgm1 Transglutaminase 1, K polypeptide 13.4
Spp1 Secreted phosphoprotein 1 12.1
Timp1 Tissue inhibitor of metalloproteinase 1 11.9
Cxcl10 Chemokine (C-X-C motif) ligand 10 11.7
Bcl3 B-cell leukemia/lymphoma 3 11.7
Chi3l1 Chitinase 3-like 1 10.8
Microarray data indicate that 13 genes are overexpressed in lesioned
hippocampi with a fold change above 10, one month after the lesion. All
are known to be involved in immune and inﬂammatory processes and in
tissue remodeling. Among these genes, 4 codes for cytokines with
demonstrated chemotactic properties: C3, Ccl2, Spp1, and Cxcl10 (bold).
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in the lower well only or in both the upper and the lower
compartments of the chamber, in order to disrupt the gradi-
ent. Similarly, in agarose spot assays, the cytokines were also
added in the medium around the drop, in order to disrupt the
cytokine gradient. Interestingly, we observed a signiﬁcant
reduction of the CCL2-dependent stimulation in gradient-
disrupted conditions (p < 0 01 for both assays) (Figures 7(a)
and 7(b)) suggesting a chemotactic eﬀect of CCL2 on
OE-MSCs. Yet, OE-MSC migration still increased in the
absence of a CCL2 gradient (p < 0 05 in modiﬁed Boyden
chambers and p < 0 01 in agarose spot assay), thus
indicating that CCL2 stimulates a combination of both
chemokinesis and chemotaxis. Importantly, no signiﬁcant
diﬀerence was observed when the SPP1 gradient was
disrupted (Figures 7(c) and 7(d)), indicating that SPP1
only acts on human OE-MSC chemokinesis.
3.7. Human OE-MSCs Express CCR1 and CCR10 but Not
CCR2. In view of our results, we decided to assess the expres-
sion in OE-MSCs of the cognate receptor of CCL2 and CCR2.
To this end, we designed RT-qPCR probes (Supplementary
Table 2) against the two isoforms of CCR2 (CCR2A and
CCR2B). Surprisingly, CCR2 mRNA was undetectable in
OE-MSCs from all three tested donors (Figure 8(a)). Of note,
the detection ofCCR2mRNA in an acutemonocytic leukemia
cell line (THP1) known to express CCR2 demonstrated the
validity of our system of analysis. To elucidate an alternative
mechanism of action bypassing the classic CCL2/CCR2 inter-
action, we measured the expression of C-C chemokine
receptors (CCRs) that can potentially bind CCL2, includ-
ing CCR1, CCR4, and CCR10. Both CCR1 and CCR10
were expressed in human OE-MSCs, thus oﬀering two
alternative ways of action for CCL2 on OE-MSCs.
4. Discussion
In a previous study, we demonstrated that a directed
migration of human OE-MSCs into the lesioned hippo-
campus accompanied the functional recovery observed
after their transplantation in an amnesic mouse model.
We reported the ability of OE-MSCs to migrate in vivo
when the transplantation was performed at a distance
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Figure 4: Conﬁrmation of cytokine overexpression in the four-week-lesioned hippocampus by RT-qPCR. Scatterplots showing relative
expression of selected cytokine transcripts in four-week-lesioned hippocampi (n = 6), in comparison with healthy hippocampi (n = 5). (a–d)
Overexpression of transcript coding for chemotactic cytokines selected after the microarray experiment (i.e., C3, Ccl2, Spp1, and Cxcl10)
was conﬁrmed by RT-qPCR. (e–h) Expression of genes known to be overexpressed in the inﬂamed brain (i.e., Gfap, F4/80, Tnfa, and Il1b)
was also assessed. Relative expression levels were determined according to the ΔΔCt method, the Gapdh gene serving as endogenous control
for normalization. Each point corresponds to one mouse. The horizontal bars indicate the mean relative gene expression. (∗p ≤ 0 05 and
∗∗p ≤ 0 01, using two-tailed Mann–Whitney U test.)
9Stem Cells International
CTRL hCCL2
(a) (b)
hSPP1
(c)
0
50
100
150
200
250
300
350
400
[hC3A] [hCCL2] [hCXCL10] [hSPP1]
CTRL CTRL CTRL40 400 4000 80 400 800 1200 8 80 8004 CTRL 40 400 40004
%
 o
f m
ig
ra
tin
g 
ce
lls
 p
er
 fi
el
d 
(%
 o
f C
TR
L)
ng/mL
⁎
⁎
⁎
⁎
⁎
⁎
⁎
⁎
⁎
⁎
⁎
⁎
⁎
0
50
100
150
200
250
300
350
400
hCCL2
 hSPP1
– – + +
– + – +
⁎
⁎
⁎
⁎
⁎
⁎
⁎
⁎
⁎
(d) (e)
CTRL hCCL2 hSPP1
(f) (g) (h)
Figure 5: Continued.
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from the injury site [13]. However, molecular mecha-
nisms regulating the recruitment and the homing of
OE-MSCs into injured brain areas had not yet been
investigated and gaining insight into these mechanisms
could improve the therapeutic potential of grafted
OE-MSCs. We provide here the ﬁrst evidence that
human OE-MSCs secrete key proteins that allow them to
cross the blood-brain barrier and are attracted by com-
ponents of the innate immune system overexpressed in
the lesioned hippocampus. We identiﬁed CCL2 as a
chemokine able to stimulate the gradient-dependent
migration of human OE-MSCs whereas the SPP1 cytokine
enhances their random motility.
To date, no study has ever reported the migration of
OE-MSCs through the blood-brain barrier. However,
according to our prior work, OE-MSCs belong to the
subgroup of ectomesenchymal cells [11], they are members
of the large family of mesenchymal cells. Interestingly, sev-
eral studies reported bone marrow mesenchymal stem cells
passing through the BBB [36–38].
Throughout the current manuscript, we use the word
“diapedesis” to evoke the passage of OE-MSCs through the
BBBmodel. This term often refers to themechanism bywhich
a cell (usually a leukocyte) ﬁnds its way between the endothe-
lial cells of a blood capillary. There is a second possibility for
crossing the BBB: the transcellular way which allows a
molecule or a cell to cross the cytoplasm of an endothelial cell
to join either the lumen of a blood vessel or an organ [39]. The
data presented here argue in favor of perforations of the
endothelial layer at the close junctions between endothelial
cells. However, the parallel existence of transcytosis cannot
be ruled out. To resolve this issue in future studies, we could
not only use video microscopy and electron microscopy but
also study the expression of proteins involved in transcellular
migration (JAM-A, PECAM-1, VCAM-1, ICAM-1, etc.) [40].
The present study identiﬁed 629 OE-MSC-secreted
proteins, more than twice the number (274) of secreted
proteins reported by a research team studying the same adult
stem cell subtype [41]. Both datasets contained 119 common
proteins while 510 were uniquely uncovered in our study.
The sensitivity of the mass spectrometer used in our experi-
ments may explain such a discrepancy. Nonetheless, both
studies underline the importance of cell migration. Indeed,
using Swiss-prot functional annotation, the previous study
observed that the largest number of secreted proteins was
associated to the cell growth and migration pathway [41].
Similarly, we report here that 239 out of 629 OE-MSC-
secreted proteins are associated to cell movement, migration,
and/or homing.
Neuroinﬂammation is a common denominator in dam-
aged cerebral areas, and cytokines associated with neuroin-
ﬂammation are known to be involved in the homing
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Figure 5: Among selected overexpressed cytokines, only CCL2 and SPP1 stimulate OE-MSC migration. Eﬀects of human recombinant
cytokines (i.e., hC3A, hCCL2, hSPP1, and hCXCL10) on human OE-MSC migration were assessed using modiﬁed Boyden chambers (a–e)
and agarose spot assay (f–j). (a–c) Representative images of membrane ﬁlter ﬁelds from modiﬁed Boyden chambers display Hoechst-
stained nuclei of migrating human OE-MSCs, 12 hours after the addition of buﬀer or cytokines (1,000 ng/mL) in the lower chamber.
Under the 40x objective, the migrating stem cells attached to the lower side of the membrane (white arrows) were easily distinguishable
from nonmigrating cells (unfocused nuclei). Scale bar: 50 μm. Mean percentage of migrating OE-MSCs per ﬁeld in response to cytokines
at increasing concentrations (d) or to a cocktail of the two active cytokines at the concentration showing maximum eﬃcacy (1,000 ng/mL)
(e). (f–h) Representative images of an area of jelliﬁed agarose drop (upper left zone) containing buﬀer or cytokines at 10μg/mL. Twenty-
four hours after plating, OE-MSCs were observed around the drop and human OE-MSCs penetrated into the drop in the presence of
active cytokines (hCCL2, hSPP1). Scale bar: 200 μm. Mean number of migrating human OE-MSCs in the drop area in response to buﬀer
or cytokines at 10μg/mL (i) or a cocktail of the two active cytokines used at the same concentration (j). Values reported are the mean
(±SEM) of at least three independent experiments performed in triplicate for modiﬁed Boyden chambers and in ten replicate drops for
agarose spot assays. (∗∗p ≤ 0 01 and ∗∗∗p ≤ 0 001, using Student’s t-test.)
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Figure 6: Mouse recombinant mCcl2 and mSpp1 cytokines also stimulate human OE-MSC migration. Eﬀects of mouse recombinant
cytokines (i.e., mCcl2 and mSpp1) on human OE-MSCs were assessed using modiﬁed Boyden chambers (a) and agarose spot assays (b).
Mean percentage of migrating human OE-MSCs per ﬁeld in response to buﬀer or cytokines at increasing concentrations, 12 hours after
the start of the experiment (a). Mean number of migrating human OE-MSCs per drop in response to buﬀer or cytokines at 10 μg/mL,
24 hours after the start of the experiment (b). Values reported are the mean (±SEM) of at least three independent experiments performed
in triplicate for modiﬁed Boyden chambers and in ten replicate drops for agarose spot assays. (∗p ≤ 0 05, ∗∗p ≤ 0 01, and ∗∗∗p ≤ 0 001,
using Student’s t-test.)
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Figure 7: CCL2 stimulates both chemokinesis and chemotaxis while SPP1mainly acts on chemokinesis. Random cell motility (chemokinesis)
and gradient-dependent cell migration (chemotaxis) of human OE-MSCs in response to human recombinant cytokines hCCL2 and hSPP1
were assessed using modiﬁed Boyden chambers (a, c) and agarose spot assays (b, d). (a, c) Mean percentage of migrating human OE-
MSCs per ﬁeld, 12 hours later, in response to buﬀer or cytokines placed either in the lower well (below) or in both the upper and the
lower wells (above and below). (b, d) Mean number of migrating human OE-MSCs per drop, 24 hours later, in response to buﬀer or
cytokines placed either in the agarose drop or in both the medium and the drop. Values reported are the mean (±SEM) of at least
three independent experiments performed in triplicate for modiﬁed Boyden chambers and in ten replicate drops for agarose spot
assays. (∗p ≤ 0 05, ∗∗p ≤ 0 01, and ∗∗∗p ≤ 0 001, using Student’s t-test.)
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mechanisms of diﬀerent types of immune, tumor, and stem
cells [42]. Thus, deciphering the inﬂammatory processes in
damaged areas is a prerequisite to understanding human
OE-MSC homing mechanisms. Histological analysis of 4-
week-lesioned hippocampi revealed a strong reactivity of
astrocytes and microglia, two major components of the brain
innate immunity [43]. As expected, lesioned areas displayed
the gene expression proﬁle of an inﬂamed structure and a
majority of overexpressed genes directly participate in
immune and inﬂammatory processes. In an attempt to eluci-
date the signals involved in OE-MSC homing, we identiﬁed
four highly overexpressed transcripts that code for two cyto-
kines (i.e., C3 and Spp1) and two chemokines (i.e., Ccl2 and
Cxcl10) known for their chemotactic properties on immune
cells or on various stem cell types.
The ﬁrst candidate, the complement component C3, is
the most overexpressed transcript of the microarray. The
complement cascade is activated in most neurological dis-
eases, including acute or chronic brain insults [44]. Comple-
ment activation from classical, alternative, and lectin
pathways leads to production of the anaphylatoxin C3a, a
small polypeptide released from the precursor protein C3
by C3 convertases. C3a anaphylatoxin is involved in inﬂam-
matory processes following focal cerebral ischemia [45] and
has been described as a chemotactic factor for mesenchymal
stem cells in vitro [46]. Similarly, SPP1, also called osteopon-
tin, exhibits strong chemoattractive and proinﬂammatory
properties [47], is upregulated in injured brain areas [48,
49], and promotes the migration of various cell types, includ-
ing astrocytes, mesenchymal stem cells, or neuroblasts from
the subventricular zone [48, 50–53]. CXCL10, a member of
the CXC chemokine family, can also attract bone marrow-
derived mesenchymal stem cells (BM-MSCs) [54], and
CXCL10-expressing cells appear in the inﬂamed central ner-
vous system after a trauma or in neurodegenerative diseases
[55]. Among the four candidates, CCL2 is the most studied
factor in terms of stem cell homing into damaged areas: it dis-
plays chemoattractive properties on numerous stem cell
types, including neural crest-derived stem cells [56], neural
stem cells [28, 29, 57, 58], and BM-MSCs [59, 60].
When we tested the eﬀects of these 4 overexpressed cyto-
kines on OE-MSC migration, the data from agarose spot
assays perfectly corroborated the ﬁndings obtained with
modiﬁed Boyden chambers. We demonstrated that human
recombinant SPP1 signiﬁcantly stimulated human OE-MSC
migration from a concentration range of 40–400ng/mL.
These results are in agreement with a previous study
showing that SPP1 increases the migration of BM-MSCs
at concentrations of 500ng/mL and above [51]. However,
other studies reported an eﬀect of SPP1 with concentrations
ranging from 10 to 20μg/mL on astrocytes [48], mesenchy-
mal stem cells [50], and neuroblasts [52, 53], in modiﬁed
Boyden chambers. This comparison highlights the high
sensitivity of human OE-MSCs to SPP1. This cytokine is
known to interact with diﬀerent cell surface receptors [47]
such as integrin β1 [51, 53] and integrin αv [49] via an
arginine-glycine-aspartate (RGD) domain or with CD44 via
an RGD-independent mechanism [50]. In a previous study
[11], we demonstrated that human OE-MSCs strongly
express integrin β1 (CD29), integrin αv (CD51), and CD44
at their surface.
In regard to the CCL2 chemokine, we demonstrated a
signiﬁcant eﬀect of human recombinant CCL2 on human
OE-MSC migration, with concentrations ranging from 80
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Figure 8: Expression of CCR receptors in human OE-MSCs suggests CCL2 acts through unsuspected pathways. (a–d) mRNA expression of
C-C chemokine receptors (CCRs) that can potentially bind CCL2 (i.e., CCR2, CCR1, CCR4, and CCR10), normalized to the ABELSON
housekeeping gene (ABL1). Values reported are the mean (±SEM) of at least three independent experiments performed in duplicate.
Expression level of each gene is represented by 2−ΔCT where ΔCT=CT (gene X)−CT (ABL1). Human OE-MSCs from three donors
(donors 1, 2, and 3) were analyzed. The acute monocytic leukemia cell line THP1 was used as positive control. ND: not detected.
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to 400ng/mL. These results are in agreement with
previous studies showing that CCL2 aﬀects neuroblasts,
at 500 ng/mL [29] or on BM-MSCs from 75ng/mL, in
modiﬁed Boyden chambers [61]. However, numerous
in vitro studies reported a CCL2 eﬀect at lower concentra-
tions (150 pg/mL to 10 ng/mL) on neuroblasts and mesen-
chymal stem cells [28, 56, 57, 59, 62, 63]. In most cases,
the studied cells expressed the CCR2 receptor. Surpris-
ingly, we did not detect the two cognate CCL2 receptors
generated by alternative splicing, namely, CCR2A and
CCR2B, in human OE-MSCs from three diﬀerent donors.
A diﬀerent picture emerges from studies on BM-MSCs, a
stem cell type closely related to OE-MSCs [11]: on these
cells, the expression of chemokine receptors and particu-
larly CCR2 varies according to culture conditions and
assessment techniques [64–67]. CCR2 expression is stimu-
lated by preincubating the BM-MSCs with inﬂammatory
cytokines [65]. However, pretreating OE-MSCs with the
proinﬂammatory cytokine TNFa or the CCL2 ligand did
not induce CCR2 expression in OE-MSCs (data not
shown). These observations suggest that CCL2 stimulates
OE-MSC migration via a CCR2-independent pathway.
Chemokines bind to a large family of receptors with vari-
ous binding aﬃnities [68, 69]. For example, although
CCR2 is the receptor with the highest aﬃnity, CCL2 can bind
to lower aﬃnity receptor, such as CCR1 [68, 70] and
CCR4 [71–73], or via unknown mechanisms [74, 75]. In
the current study, using RT-qPCR, we observed a weak
expression of CCR1 while CCR4 transcripts were undetect-
able. Unpublished microarray data obtained on OE-MSCs
indicate that CCR10 is the most highly expressed C-C
chemokine receptors (CCR) in these cells. Here, we con-
ﬁrmed its expression in OE-MSCs using RT-qPCR.
Although CCR10 is mainly known to bind CCL27 and
CCL28 with high aﬃnity [76], CCL2 may nonetheless bind
to and activate CCR10 in OE-MSCs, through a yet
unknown pathway.
When comparing the eﬀects of CCL2 and SPP1 on OE-
MSC migration, we observed that CCL2 is more potent
and is the prime candidate to explain OE-MSC homing into
the lesioned hippocampus. It is now established that a mol-
ecule can aﬀect cell migration by stimulating either random
motility (i.e., chemokinesis) or concentration-dependent-
directed migration (i.e., chemotaxis) or a combination of
both [77]. The CCL2 chemokine is eﬃcient on OE-MSC
migration in the presence of a chemokine gradient, suggest-
ing that CCL2 eﬀects are mainly chemotactic, whereas SPP1
induces similar responses in the presence or absence of a
gradient, demonstrating that its eﬀects are mainly chemoki-
netic. Moreover, at the concentration showing the maximum
eﬃcacy for the two cytokines, CCL2 is more potent than
SPP1 and a cocktail of both cytokines does not increase
CCL2 eﬀects. The concentration required to stimulate the
in vitro migration of human OE-MSCs suggests that the
potential eﬀect of these cytokines in vivo may be restricted
to major physiopathological inﬂamed conditions. However,
we cannot exclude that OE-MSCs express higher levels or
new chemokine receptors when they are grafted into the
brain. Alternatively, cocktails of several other chemokines,
expressed at lower level in the inﬂamed hippocampus, may
also exert chemotactic eﬀects.
In a previous study, we successfully demonstrated the
therapeutic potential of human OE-MSCs grafted in a
murine model of amnesia [13]. Therefore, we decided to
assess the chemoattractive potential of human and murine
cytokines. In regard to CCL2, comparing the amino-acid
sequences between human and murine CCL2 indicates a
55% identity and an 81% similarity [78]. Predictably, we
demonstrated here that mouse and human recombinant
CCL2 induce similar eﬀects on human OE-MSC migration.
This ﬁnding is in line with a prior study showing that human
and murine cytokines are equiactive on human monocytes
[79]. Concerning SPP1, comparing the amino-acid sequences
between human and murine SPP1 indicates a 64% identity
and an 81% similarity [80]. Like CCL2, we show here that
mouse and human recombinant SPP1 stimulate human
OE-MSC migration.
5. Conclusion
In summary, we bring the ﬁrst evidence that human
OE-MSCs express transmigration-associated proteins, cross
the blood-brain barrier, and respond to cytokines overex-
pressed in lesioned hippocampi, such as CCL2 and SPP1.
We also discovered which cerebral constituents may attract
OE-MSCs and be responsible, at least partially, for their
homing into sites of cerebral injuries. These new data might
be proven crucial for improving the therapeutic potential of
OE-MSCs with a view to repairing the pathological or
traumatized human brain.
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